Archive · 5 Dec 2025
Renuka Iyer Named New CMO for NCCN
Renuka Iyer, a well-known doctor specializing in cancer treatment, has been chosen as the new Chief Medical Officer for the National Comprehensive Cancer Network (NCCN).
NCCN is a group of top cancer centers that create guidelines for cancer care.
Dr. Iyer has worked at Roswell Park Comprehensive Cancer Center and has published many research papers.
She will start her new job in February 2026.
Her role will include leading the NCCN Guidelines program, which helps doctors and patients with cancer treatment information.
Dr. Iyer is excited about this opportunity to improve cancer care and make information more accessible.
Renuka Iyer, MD, has been appointed as the new Chief Medical Officer for the National Comprehensive Cancer Network (NCCN).
Dr. Iyer currently serves as a Professor of Oncology at Roswell Park Comprehensive Cancer Center and has a long history of leadership in oncology.
She has published hundreds of peer-reviewed articles and focuses her research on novel therapies for rare cancers, immunotherapy, biomarkers, and quality of life.
Dr. Iyer will start her new role on February 26, 2026, and will provide clinical leadership for the NCCN Guidelines program.
The NCCN Guidelines program consists of 90 guidelines for treating nearly every type of cancer, along with prevention, screening, and supportive care.
- Who
- Renuka Iyer, MD
- What
- Appointed as the new Chief Medical Officer for the National Comprehensive Cancer Network (NCCN)
- When
- Starts on February 26, 2026
- Where
- NCCN, based in Plymouth Meeting, Pa.
- Why
- To provide clinical leadership for the NCCN Guidelines program and oversee additional point-of-care resources
- Organization
- National Comprehensive Cancer Network (NCCN)
- New Appointment
- Renuka Iyer, MD, as Chief Medical Officer (CMO)
- Current Role
- Professor of Oncology at Roswell Park Comprehensive Cancer Center
- Education
- Grant Medical College, University of Mumbai; Residency at Cornell University School of Medicine
- Research Focus
- Novel therapies for rare cancers, immunotherapy, biomarkers, and quality of life
- Start Date
- February 26, 2026
- NCCN Guidelines
- 90 guidelines for treating nearly every type of cancer